P06 Competing CNS or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients on Afatinib in LUX-Lung 3, 6, and 7

CNS metastases are known complications of advanced EGFR mutation-positive NSCLC, thus, LUX-Lung (LL) trials investigating afatinib allowed enrolment of patients with brain metastases (BM). LL3, 6 and 7 previously demonstrated activity of afatinib in patients with BM, with the magnitude of progression-free survival (PFS) improvement with afatinib vs chemotherapy or gefitinib in patients with BM being similar to that observed in patients without BM (HR 0.54, 0.47, and 0.76 in LL3, 6 and 7, respectively). PFS was significantly improved with afatinib vs chemotherapy in a combined analysis of LL3 and 6 in patients with asymptomatic BM (HR 0.50, p=0.0297).1 To investigate whether afatinib can prevent CNS progression or metastasis, competing risk analyses for the progression and metastasis pattern in the CNS or non-CNS region were carried out in patients with and without BM in LL3, 6 and 7.